Nothing Special   »   [go: up one dir, main page]

WO2008068507A3 - 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment - Google Patents

2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment Download PDF

Info

Publication number
WO2008068507A3
WO2008068507A3 PCT/GB2007/004697 GB2007004697W WO2008068507A3 WO 2008068507 A3 WO2008068507 A3 WO 2008068507A3 GB 2007004697 W GB2007004697 W GB 2007004697W WO 2008068507 A3 WO2008068507 A3 WO 2008068507A3
Authority
WO
WIPO (PCT)
Prior art keywords
raf
pyrid
phenylamino
protein kinase
kinase inhibitors
Prior art date
Application number
PCT/GB2007/004697
Other languages
French (fr)
Other versions
WO2008068507A2 (en
Inventor
Brian Aquila
Donald James Cook
Craig Johnstone
Stephen Lee
Paul Lyne
David Alan Rudge
Melissa Vasbinder
Haixia Wang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Brian Aquila
Donald James Cook
Craig Johnstone
Stephen Lee
Paul Lyne
David Alan Rudge
Melissa Vasbinder
Haixia Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008068507(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Brian Aquila, Donald James Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang filed Critical Astrazeneca Ab
Publication of WO2008068507A2 publication Critical patent/WO2008068507A2/en
Publication of WO2008068507A3 publication Critical patent/WO2008068507A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to chemical compounds of the formula (I): or pharmaceutically or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
PCT/GB2007/004697 2006-12-08 2007-12-07 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment WO2008068507A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86924106P 2006-12-08 2006-12-08
US60/869,241 2006-12-08
US98573207P 2007-11-06 2007-11-06
US60/985,732 2007-11-06

Publications (2)

Publication Number Publication Date
WO2008068507A2 WO2008068507A2 (en) 2008-06-12
WO2008068507A3 true WO2008068507A3 (en) 2008-07-31

Family

ID=39386079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004697 WO2008068507A2 (en) 2006-12-08 2007-12-07 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment

Country Status (5)

Country Link
AR (1) AR064208A1 (en)
CL (1) CL2007003557A1 (en)
PE (1) PE20081351A1 (en)
TW (1) TW200829566A (en)
WO (1) WO2008068507A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
CN101652352A (en) * 2006-12-22 2010-02-17 诺瓦提斯公司 Quinazolines for PDK1 inhibition
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
WO2008128995A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
CN101663299A (en) 2007-04-23 2010-03-03 詹森药业有限公司 Thiophene (two) azole compounds as fast dissociating dopamine 2 receptor antagonists
KR101609218B1 (en) 2008-07-31 2016-04-05 얀센 파마슈티카 엔.브이. Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
MX2011008549A (en) 2009-02-13 2011-12-06 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors.
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2017001626A1 (en) 2015-06-30 2017-01-05 British Telecommunications Public Limited Company Quality of service management in a network
US11198910B2 (en) 2016-09-02 2021-12-14 New England Biolabs, Inc. Analysis of chromatin using a nicking enzyme
CN111170986A (en) * 2018-11-13 2020-05-19 北京睿熙生物科技有限公司 Inhibitors of bruton's tyrosine kinase
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037285A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
WO2006039718A2 (en) * 2004-10-01 2006-04-13 Amgen Inc Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037285A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
WO2006039718A2 (en) * 2004-10-01 2006-04-13 Amgen Inc Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIMAURO, ERIN ET AL: "Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity", J.MED.CHEM, vol. 49, no. 19, 2006, pages 5671 - 5686, XP002480947 *

Also Published As

Publication number Publication date
WO2008068507A2 (en) 2008-06-12
PE20081351A1 (en) 2008-11-26
AR064208A1 (en) 2009-03-18
CL2007003557A1 (en) 2008-08-01
TW200829566A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2006067445A3 (en) Csf-1r kinase inhibitors
MX2007008924A (en) Chemical compounds.
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
TW200621259A (en) Chemical compounds
TW200621730A (en) Chemical compounds
TW200736234A (en) Chemical compounds
MX2009004908A (en) Chemical compounds.
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
TW200621762A (en) Novel compounds
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NO20070199L (en) Substituted quinazolones as anti-cancer agents
WO2010021918A8 (en) Compounds as kinase inhibitors
MX2009002010A (en) Heteroaryl derivatives as protein kinase inhibitors.
MX2009008953A (en) Spiro substituted compounds as angiogenesis inhibitors.
MX2009009843A (en) Spiro substituted compounds as angiogenesis inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824807

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07824807

Country of ref document: EP

Kind code of ref document: A2